IMDS laser breast imaging technology presented at China's leading breast disease conference | Oncology
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Communities Oncology IMDS laser breast imaging technology presented at China's leading breast disease conference

IMDS laser breast imaging technology presented at China's leading breast disease conference

Specialties
Imaging Diagnostic Systems, Inc. participated in the 2nd National Imaging Diagnostic Conference on Breast Disease in Qingdao, China, May 25-27, 2007. The Conference is considered the most important venue on breast disease in China. Imaging Diagnostic Systems, Inc. participated in the 2nd National Imaging Diagnostic Conference on Breast Disease in Qingdao, China, May 25-27, 2007. The Conference is considered the most important venue on breast disease in China.

Dr. Run-Xian Bao, Chairman of the Tianjin Tumor Hospital Radiology Department, the largest breast disease center in China, gave an introductory presentation on the new CT Laser Mammography clinical technology. The CTLM presentation was published in the collective articles of the conference.

"Approximately 180 doctors attended this conference, the leaders in the study of breast cancer. Many were very interested in how CT Laser Mammography systems could help improve cancer detection methods or be used to track a patient's progress through neoadjuvant therapy," stated Mr. Jing Jie Zhuang, Managing Director, IDSI Beijing.

"We are very pleased with the growing interest we are seeing as we build our clinical presence in China. Having a direct office in Beijing has greatly helped IMDS establish close relations with leading Chinese breast specialists for both research and commercial opportunities. Beijing Friendship Hospital has been a key CTLM clinical collaborator," Zhuang continued.

IMDS has received approval for the CTLM system from the State Food and Drug Administration of the People's Republic of China (SFDA), the Chinese equivalent of the US Food and Drug Administration. As announced previously, according to the Beijing Municipal Commission of Development & Reform and the Beijing Municipal Health Bureau, CTLM procedures may be priced up to RMB300 ($38 at the current exchange rate) per breast as listed on the 'Interim Procedures for Beijing Medical Service Price' schedule.
 

Related Articles